collection
https://read.qxmd.com/read/33333134/the-neurobiology-of-abstinence-induced-reward-seeking-in-males-and-females
#1
REVIEW
Yanaira Alonso-Caraballo, Suman K Guha, Elena H Chartoff
Drugs of abuse and highly palatable foods (e.g. high fat or sweet foods) have powerful reinforcing effects, which can lead to compulsive and addictive drives to ingest these substances to the point of psychopathology and self-harm--specifically the development of Substance Use Disorder (SUD) and obesity. Both SUD and binge-like overeating can be defined as disorders in which the salience of the reward (food or drug) becomes exaggerated relative to, and at the expense of, other rewards that promote well-being...
January 2021: Pharmacology, Biochemistry, and Behavior
https://read.qxmd.com/read/33360046/clusterin-always-protecting-synthesis-function-and-potential-issues
#2
REVIEW
Carmen Rodríguez-Rivera, Miguel M Garcia, Miguel Molina-Álvarez, Carmen González-Martín, Carlos Goicoechea
In the last years, clusterin, a challenging and paradoxical apolipoprotein, has been of growing interest amongst a rising number of scientists. This enigmatic protein is present in all fluids of the organism besides within the intracellular matrix, and it plays diverse, and at times contrary, roles in a growing number of pathologies. It seems to vary its location and function to assure cellular survival being cytoprotective hence its significance in neuroprotection and cancer along with chemotherapy resistance...
December 24, 2020: Biomedicine & Pharmacotherapy
https://read.qxmd.com/read/29132050/cannabinoid-hyperemesis-syndrome-review-of-the-literature-and-of-cases-reported-to-the-french-addictovigilance-network
#3
REVIEW
Benoît Schreck, Nicolas Wagneur, Pascal Caillet, Marie Gérardin, Jennyfer Cholet, Michel Spadari, Nicolas Authier, Juliana Tournebize, Marion Gaillard, Anais Serre, Louise Carton, Stéphanie Pain, Pascale Jolliet, Caroline Victorri-Vigneau
BACKGROUND: Cannabinoid hyperemesis syndrome is a variant of cyclical vomiting syndrome in a context of chronic cannabis usage. Our aim was to compare French cases to those identified in the international literature in order to further our knowledge of the clinical criteria, pathophysiology and treatments for cannabinoid hyperemesis syndrome. METHODS: We analysed cases reported in the international literature up to 30 June 2017, obtained from the MEDLINE, PsycINFO and The Cochrane Library databases; we selected relevant articles based on title and abstract...
January 1, 2018: Drug and Alcohol Dependence
https://read.qxmd.com/read/33160719/intravenous-haloperidol-versus-ondansetron-for-cannabis-hyperemesis-syndrome-havoc-a-randomized-controlled-trial
#4
Aaron J Ruberto, Marco L A Sivilotti, Savannah Forrester, Andrew K Hall, Frances M Crawford, Andrew G Day
STUDY OBJECTIVE: Little is known about the cause or optimal treatment of hyperemesis in habitual cannabis users. Anecdotal evidence supports the use of haloperidol over traditional antiemetics for this newly recognized disorder. We compare haloperidol with ondansetron for cannabis hyperemesis syndrome. METHODS: We randomized cannabis users with active emesis to either haloperidol (with a nested randomization to either 0.05 or 0.1 mg/kg) or ondansetron 8 mg intravenously in a triple-blind fashion...
November 5, 2020: Annals of Emergency Medicine
https://read.qxmd.com/read/32616214/antidepressant-mechanisms-of-ketamine-focus-on-gabaergic-inhibition
#5
REVIEW
Bernhard Luscher, Mengyang Feng, Sarah J Jefferson
There has been much recent progress in understanding of the mechanism of ketamine's rapid and enduring antidepressant effects. Here we review recent insights from clinical and preclinical studies, with special emphasis of ketamine-induced changes in GABAergic synaptic transmission that are considered essential for its antidepressant therapeutic effects. Subanesthetic ketamine is now understood to exert its initial action by selectively blocking a subset of NMDA receptors on GABAergic interneurons, which results in disinhibition of glutamatergic target neurons, a surge in extracellular glutamate and correspondingly elevated glutamatergic synaptic transmission...
2020: Advances in Pharmacology
https://read.qxmd.com/read/31698932/buprenorphine-for-cancer-pain-in-patients-with-nonmedical-opioid-use-a-retrospective-study-at-a-comprehensive-cancer-center
#6
Eric Hansen, Chitra Nadagoundla, Chong Wang, Austin Miller, Amy Allen Case
BACKGROUND: Outpatients with cancer commonly have nonmedical opioid use (NMOU) behaviors and use opioids to dull emotional and existential suffering. Buprenorphine is often used for cancer pain due to less reported euphoria when compared to other opioids. METHODS: A retrospective review was done in patients who were prescribed buprenorphine for cancer pain. Pain scores were reported on a Likert pain scale of 1 to 10. Nonmedical opioid use was defined as patients taking opioids for emotional pain at or above the maximum prescribed amount...
May 2020: American Journal of Hospice & Palliative Care
https://read.qxmd.com/read/31757518/anticipation-of-monetary-reward-in-amygdala-insula-caudate-are-predictors-of-pleasure-sensitivity-to-d-amphetamine-administration
#7
RANDOMIZED CONTROLLED TRIAL
Scott A Langenecker, Leah R Kling, Natania A Crane, Stephanie M Gorka, Robin Nusslock, Katherine S F Damme, Jessica Weafer, Harriet de Wit, K Luan Phan
BACKGROUND: Drug addiction and dependence continue as an unresolved source of morbidity and mortality. Two approaches to identifying risk for abuse and addiction are psychopharmacological challenge studies and neuroimaging experiments. The present study combined these two approaches by examining associations between self-reported euphoria or liking after a dose of d-amphetamine and neural-based responses to anticipation of a monetary reward. METHODS: Healthy young adults (N = 73) aged 19 and 26, without any history of alcohol/substance dependence completed four laboratory sessions in which they received oral d-amphetamine (20 mg) or placebo, and completed drug effect questionnaires...
January 1, 2020: Drug and Alcohol Dependence
https://read.qxmd.com/read/31994019/kratom-pharmacology-clinical-implications-and-outlook-a-comprehensive-review
#8
REVIEW
Steven C Eastlack, Elyse M Cornett, Alan D Kaye
Kratom, or Mitragyna, is a tropical plant indigenous to Southeast Asia, with unique pharmacological properties. It is commonly consumed by preparing the leaves into decoction or tea, or by grinding them into a powder. Recent evidence has revealed that kratom has physiological effects similar to opioids, including pain relief and euphoria, as well as stimulant properties, which together raise potential concern for dependence and addiction. Moreover, growing evidence suggests that the prevalence of kratom use is increasing in many parts of the world, raising important considerations for healthcare providers...
June 2020: Pain and Therapy
https://read.qxmd.com/read/32483988/clinical-data-for-the-use-of-cannabis-based-treatments-a-comprehensive-review-of-the-literature
#9
REVIEW
Shannon Inglet, Bradly Winter, Sarah E Yost, Sophia Entringer, Anh Lian, Meryl Biksacky, Renee D Pitt, Whitney Mortensen
OBJECTIVE: To compile and synthesize the available literature describing medical cannabis use across various disease states. DATA SOURCES: PubMed, EBSCO, and Google Scholar searches were conducted using MeSH and/or keywords. STUDY SELECTION AND DATA EXTRACTION: Studies were included if they described the use of cannabis-based products and medications in the treatment of a predefined list of disease states in humans and were published in English...
November 2020: Annals of Pharmacotherapy
https://read.qxmd.com/read/32671427/signaling-mechanisms-of-%C3%AE-opioid-receptor-mor-in-the-hippocampus-disinhibition-versus-astrocytic-glutamate-regulation
#10
REVIEW
Min-Ho Nam, Woojin Won, Kyung-Seok Han, C Justin Lee
μ-opioid receptor (MOR) is a class of opioid receptors that is critical for analgesia, reward, and euphoria. MOR is distributed in various brain regions, including the hippocampus, where traditionally, it is believed to be localized mainly at the presynaptic terminals of the GABAergic inhibitory interneurons to exert a strong disinhibitory effect on excitatory pyramidal neurons. However, recent intensive research has uncovered the existence of MOR in hippocampal astrocytes, shedding light on how astrocytic MOR participates in opioid signaling via glia-neuron interaction in the hippocampus...
July 15, 2020: Cellular and Molecular Life Sciences: CMLS
https://read.qxmd.com/read/32870152/the-%C3%AE-opioid-receptor-gene-polymorphism-118a-g-weakens-the-pharmacological-action-of-buprenorphine
#11
Hiromitsu Imai, Misaki Morita, Hajime Morita, Tetsuji Ohyama, Shimako Tanaka, Shinya Uchida, Noriyuki Namiki, Naoto Uemura, Kyoichi Ohashi
AIMS: Opioids are commonly used analgesics for moderate to severe pain, but levels of drug effect vary among individuals. As for the mechanisms underlying these individual differences, there have been reports suggesting effects of polymorphisms in the gene encoding μ-opioid receptor ( OPRM1 ). However, whether these polymorphisms affect the actions of μ-opioid receptor partial agonists has yet to be determined. This study aimed to assess differences in the pharmacological actions of buprenorphine, a μ-opioid receptor partial agonist, due to a polymorphism (A118G, rs1799971) in the OPRM1 gene in humans...
November 2020: International Journal of Clinical Pharmacology and Therapeutics
https://read.qxmd.com/read/25013755/targeting-the-glutamatergic-system-to-treat-pathological-gambling-current-evidence-and-future-perspectives
#12
REVIEW
Mauro Pettorruso, Luisa De Risio, Giovanni Martinotti, Marco Di Nicola, Filippo Ruggeri, Gianluigi Conte, Massimo Di Giannantonio, Luigi Janiri
Pathological gambling or gambling disorder has been defined by the DSM-5 as a behavioral addiction. To date, its pathophysiology is not completely understood and there is no FDA-approved treatment for gambling disorders. Glutamate is the principal excitatory neurotransmitter in the nervous system and it has been recently involved in the pathophysiology of addictive behaviors. In this paper, we review the current literature on a class of drugs that act as modulating glutamate system in PG. A total of 19 studies have been included, according to inclusion and exclusion criteria...
2014: BioMed Research International
https://read.qxmd.com/read/32601455/impaired-glutamate-homeostasis-in-the-nucleus-accumbens-in-human-cocaine-addiction
#13
Etna J E Engeli, Niklaus Zoelch, Andreas Hock, Carlos Nordt, Lea M Hulka, Matthias Kirschner, Milan Scheidegger, Fabrizio Esposito, Markus R Baumgartner, Anke Henning, Erich Seifritz, Boris B Quednow, Marcus Herdener
Cocaine addiction is characterized by overwhelming craving for the substance, which drives its escalating use despite adverse consequences. Animal models suggest a disrupted glutamate homeostasis in the nucleus accumbens to underlie addiction-like behavior. After chronic administration of cocaine, rodents show decreased levels of accumbal glutamate, whereas drug-seeking reinstatement is associated with enhanced glutamatergic transmission. However, due to technical obstacles, the role of disturbed glutamate homeostasis for cocaine addiction in humans remains only partially understood, and accordingly, no approved pharmacotherapy exists...
June 29, 2020: Molecular Psychiatry
https://read.qxmd.com/read/32702182/roles-of-dopamine-and-glutamate-co-release-in-the-nucleus-accumbens-in-mediating-the-actions-of-drugs-of-abuse
#14
REVIEW
Silas A Buck, Mary M Torregrossa, Ryan W Logan, Zachary Freyberg
Projections of ventral tegmental area dopamine (DA) neurons to the medial shell of the nucleus accumbens have been increasingly implicated as integral to the behavioral and physiological changes involved in the development of substance use disorders (SUDs). Recently, many of these nucleus accumbens-projecting DA neurons were found to also release the neurotransmitter glutamate. This glutamate co-release from DA neurons is critical in mediating the effect of drugs of abuse on addiction-related behaviors. Potential mechanisms underlying the role(s) of dopamine/glutamate co-release in contributing to SUDs are unclear...
July 23, 2020: FEBS Journal
https://read.qxmd.com/read/32717192/corydaline-and-l-tetrahydropalmatine-attenuate-morphine-induced-conditioned-place-preference-and-the-changes-in-dopamine-d-2-and-glua1-ampa-receptor-expression-in-rats
#15
Wei-Ning Jiang, Xiao Jing, Man Li, Hong Deng, Tao Jiang, Ke-Zhao Xiong, Ying Chen, Xiao-Fei Wang, Quan-Jun Wang
Corydalis is a Chinese herb that has been used in China for hundreds of years for analgesic and other purposes. Corydaline and l-tetrahydropalmatine (l-THP) are the main active ingredients of Corydalis. This study was aimed to study the potential utility of corydaline and l-THP in the treatment of opioid abuse and addiction and explore the possible mechanisms underlying their pharmacological actions. Conditioned place preference (CPP) was used to evaluate the rewarding effects of morphine and Western-blot immunoreactive assays were used to evaluate morphine-induced changes in dopamine D2 receptor and GluA1 AMPA receptor and GluA2 AMPA receptor expression in the brain of rats...
July 25, 2020: European Journal of Pharmacology
https://read.qxmd.com/read/24622471/contribution-of-adenylyl-cyclase-modulation-of-pre-and-postsynaptic-gaba-neurotransmission-to-morphine-antinociception-and-tolerance
#16
Erin N Bobeck, QiLiang Chen, Michael M Morgan, Susan L Ingram
Opioid inhibition of presynaptic GABA release in the ventrolateral periaqueductal gray (vlPAG) activates the descending antinociception pathway. Tolerance to repeated opioid administration is associated with upregulation of adenylyl cyclase activity. The objective of these studies was to test the hypothesis that adenylyl cyclase contributes to opioid tolerance by modulating GABA neurotransmission. Repeated microinjections of morphine or the adenylyl cyclase activator NKH477 into the vlPAG decreased morphine antinociception as would be expected with the development of tolerance...
August 2014: Neuropsychopharmacology
https://read.qxmd.com/read/32755331/neurophysiological-response-properties-of-medullary-pain-control-neurons-following-chronic-treatment-with-morphine-or-oxycodone-modulation-by-acute-ketamine
#17
Hanna Viisanen, Tuomas O Lilius, Boriss Sagalajev, Pekka Rauhala, Eija Kalso, Antti Pertovaara
Descending facilitatory circuitry that involves the rostroventromedial medulla (RVM) exerts a significant role in the development of antinociceptive tolerance and hyperalgesia following chronic morphine treatment. The role of the RVM in the development of antinociceptive tolerance to oxycodone, another clinically used strong opioid, is not yet known. Ketamine, an N -methyl-d-aspartate (NMDA) receptor antagonist, attenuates opioid antinociceptive tolerance, but its effect on RVM cell discharge in opioid-tolerant animals is not known...
September 1, 2020: Journal of Neurophysiology
https://read.qxmd.com/read/32774804/thymoquinone-from-nigella-sativa-to-a-protective-pharmacological-compound-in-managing-opioid-dependence-and-amphetamine-type-stimulant-issues
#18
REVIEW
Liyana Hazwani Mohd Adnan, Nor Hidayah Abu Bakar, Nordin Simbak, Nasir Mohamad, Rusli Ismail, Nor Zidah Ahmad, Nor Suliana Mustafa, Nurul Farah Aina Md Fauzi
Opioids, amphetamines, and other types of substances have been widely abused around the world. Opioid dependence and tolerance are two distinct phenomena that have been associated with substance abuse issues. The management of its adverse consequences is becoming more challenging. More and more people are treated in Methadone Maintenance Therapy (MMT) program yet the issues are still unresolved. Researchers are continuing to study the best formulation in treating opioid dependent people starting with modern and alternative drug therapies...
July 2020: Iranian Journal of Basic Medical Sciences
https://read.qxmd.com/read/32776315/non-opioid-treatments-for-opioid-use-disorder-rationales-and-data-to-date
#19
Reda M Chalhoub, Peter W Kalivas
Opioid use disorder (OUD) represents a major public health problem that affects millions of people in the USA and worldwide. The relapsing and recurring aspect of OUD, driven by lasting neurobiological adaptations at different reward centres in the brain, represents a major obstacle towards successful long-term remission from opioid use. Currently, three drugs that modulate the function of the opioidergic receptors, methadone, buprenorphine and naltrexone have been approved by the US Food and Drug Administration (FDA) to treat OUD...
October 2020: Drugs
https://read.qxmd.com/read/32789069/tramadol-for-the-management-of-opioid-withdrawal-a-systematic-review-of-randomized-clinical-trials
#20
REVIEW
Kaushal Shah, Billy Stout, Hunter Caskey
The increase in the prescription of opioid medications has resulted in a wildfire of misuse of opioids, both for medical and non-medical reasons, with over 1.7 million people in the United States (US) suffering from distinct disorders owing to opioid use. While various medications, such as methadone, buprenorphine, and naloxone, among others, have been used in treating opioid withdrawal symptoms, concerns of the potential abuse of these drugs, the cost of procurement, legislations, and prescription policies have risen...
July 11, 2020: Curēus
label_collection
label_collection
2001
1
2
2020-08-28 22:49:47
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"